API
< Back to situation

[REVISION HISTORY]

Shanghai gene‑editing trial fatality

10 recorded revisions of this situation.

What changed

2026-08-05 08:04 UTC → 2026-08-10 01:06 UTC · added removed

In March 2025 2025, a six‑year‑old six-year-old girl, identified as “Mei”, received “Mei,” died seven days after receiving an experimental in‑vivo base‑editing in-vivo base-editing therapy at Shanghai’s Xinhua Hospital to correct a CHD3 mutation causing Snijders‑Blok‑Campeau Snijders-Blok-Campeau syndrome. Her parents paid roughly approximately US$860,000 for the intrathecal AAV‑vector AAV-vector infusion. Seven days later she suffered a severe immune reaction The hospital’s ethics board and died; hospital records later classified subsequent reports concluded the death as “definitely related” was definitely related to the infusion. treatment, specifically attributing it to microangiopathic thrombosis caused by the high-dose viral vector. Investigations by *Science* and Retraction Watch *Retraction Watch* revealed that the outcome fatality was deliberately concealed: the trial omitted from a related *Nature* paper and was not updated on ClinicalTrials.gov and ClinicalTrials.gov, leading to allegations that the research team attempted to present a related Nature paper omitted any mention false impression of the fatality. therapy's safety. While Shanghai Jiao‑Tong Jiao-Tong University’s School of Medicine created established a special working group to review the case, while case and the municipal health commission fined the hospital 24,000 yuan (≈US$3,500). No (≈US$3,500), no public disciplinary action has been taken against lead researcher Zilong Qiu. A follow‑up report dated 31 July 2026 confirmed microangiopathic thrombosis caused by The incident has sparked significant scrutiny of China’s biotechnology sector and its regulatory oversight. Industry leaders have warned that the high‑dose AAV vector as tragedy could trigger a regulatory backlash, potentially restricting the mechanism flexibility of death. investigator-initiated clinical trials. The incident case has also reignited global bio‑ethics debate over “n‑of‑1” bioethical debates regarding “n-of-1” human gene‑editing gene-editing trials, prompting calls for correction or retraction of the Nature article informed consent, and the necessity for stricter regulatory oversight. transparency in academic publishing.

Versions

  1. 2026-08-10 01:06 UTC Shanghai gene‑editing trial fatality
  2. 2026-08-05 08:04 UTC Shanghai gene‑editing trial fatality
  3. 2026-08-02 03:06 UTC Shanghai gene‑editing trial fatality
  4. 2026-07-31 04:33 UTC Shanghai gene‑editing trial fatality
  5. 2026-07-30 05:35 UTC Shanghai gene‑editing trial fatality
  6. 2026-07-29 05:18 UTC Shanghai gene‑editing trial fatality
  7. 2026-07-27 21:34 UTC Shanghai gene‑editing trial fatality
  8. 2026-07-27 21:01 UTC Shanghai gene‑editing trial fatality
  9. 2026-07-27 20:51 UTC Shanghai gene‑editing trial fatality
  10. 2026-07-27 01:27 UTC Shanghai gene‑editing trial fatality
  11. 2026-07-26 18:28 UTC Shanghai gene‑editing trial fatality

Select a version to see what changed compared to the one before it.